Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma

Journal of Urology

Volumn 173, Issue 5, 2005, Pages 1496-1501

  Kim, Hyung L ^a   Seligson, David ^b   Liu, Xueli ^c   Janzen, Nicolette ^b   Bui, Matthew H T ^b   Yu, Hong ^b   Shi, Tao ^b   Belldegrun, Arie S ^b   Horvath, Steve ^b   Figlin, Robert A ^b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carcinoma, renal cell; Kidney; Kidney neoplasms; Proteins; Tumor markers, biological

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; CARBONIC ANHYDRASE 12; GELSOLIN; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 10; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SAMPLE SIZE; SEQUENCE HOMOLOGY; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; THEORETICAL MODEL;

EID: 20244386849     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000154351.37249.f0     Document Type: Article

References (20)

1. Pyrhonen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T. et al: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol, 17: 2859, 1999
2. Fisher, R. I., Rosenberg, S. A. and Fyfe, G.: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, suppl., 6: S55, 2000
3. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E. et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med, 313: 1485, 1985
4. Zisman, A. and deKernion, J. B.: Historical perspective: past, present and future. In: Renal and Adrenal Tumors - Biology and Management. Edited by A. Belldegrun, A. Ritchie, R. Figlin et al. New York: Oxford University Press, pp. 3-16, 2003
5. Mickisch, G. H., Garin, A., van Poppel, H., de Prijck, L., Sylvester, R. and European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet, 358: 966, 2001
6. Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C. et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med, 345: 1655, 2001
7. Kim, H. L., Seligson, D., Liu, X., Janzen, N., Bui, M. H., Yu, H. et al: Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res, 10: 5464, 2004
8. Guinan, P., Sobin, L. H., Algaba, F., Badellino, F., Kameyama, S., MacLennan, G. et al: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer, 80: 992, 1997
9. Pantuck, A. J., Zisman, A., Dorey, F., Chao, D. H., Han, K.-r., Said, J. et al: Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol, 169: 2076, 2003
10. Fuhrman, S. A., Lasky, L. C. and Limas, C.: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol, 6: 655, 1982
11. Zisman, A., Pantuck, A. J., Dorey, F., Said, J. W., Shvarts, O., Quintana, D. et al: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol, 19: 1649, 2001
12. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S. et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4: 844, 1998
13. Harrell, F.: Regression Modeling Strategies: With Application to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer-Verlag, 2001
14. Zolota, V., Tsamandas, A. C., Melachrinou, M., Batistatou, A. and Scopa, C.: Expression of CD44 protein in renal cell carcinomas: association with p53 expression. Urol Oncol, 7: 13, 2002
15. Selden, L. A., Kinosian, H. J., Newman, J., Lincoln, B., Hurwitz, C., Gershman, L. C. et al: Severing of F-actin by the amino-terminal half of gelsolin suggests internal cooperativity in gelsolin. Biophys J, 75: 3092, 1998
16. Papadopoulos, I., Weichert-Jacobsen, K., Wacker, H. H. and Sprenger, E.: Correlation between DNA ploidy, proliferation marker Ki-67 and early tumor progression in renal cell carcinoma. A prospective study. Eur Urol, 31: 49, 1997
17. Aaltomaa, S., Lipponen, P., Ala-Opas, M., Eskelinen, M. and Syrjanen, K.: Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol, 31: 350, 1997
18. Yuba, H., Okamura, K., Ono, Y. and Ohshima, S.: Growth fractions of human renal cell carcinoma defined by monoclonal antibody Ki-67. Predictive values for prognosis. Int J Urol, 8: 609, 2001
19. Wada, Y., Igawa, M., Shiina, H., Shigeno, K., Yokogi, H., Urakami, S. et al: Comparison of chromosomal aberrations detected by fluorescence in situ hybridization with clinical parameters, DNA ploidy and Ki 67 expression in renal cell carcinoma. Br J Cancer, 77: 2003, 1998
20. Yao, M., Yoshida, M., Kishida, T., Nakaigawa, N., Baba, M., Kobayashi, K. et al: VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst, 94: 1569, 2002